AbbVie Posts Revenue Beat as Humira Sales Tumble. Other Immunology Drugs Are Selling.

AbbVie beat revenue expectations for its fiscal fourth quarter and raised its long-term sales outlook for two of its biggest immunology drugs. AbbVie posted fourth-quarter earnings of $2.79 a share, which were in line with analysts’ expectations but down from $3.60 a share last year. “2024 is an exciting year for AbbVie as we are well positioned to fully absorb Humira erosion and achieve modest operational revenue growth, followed by a return to robust growth in 2025,” Chief Executive Richard Gonzalez said in a press release.